Nyhetsarkiv

  • DATA PRESENTED AT ADA SHOWED THAT BASAL INSULIN THERAPY WITH LANTUS® ACHIEVED TARGET GLYCAEMIC CONTROL IN POORLY CONTROLLED TYPE 2 DIABETES

    Two studies show insulin glargine control of HbA1C in poorly controlled type 2 diabetes patients, with comparable rates of hypoglycemia Data presented today at the 65th Session of the American Diabetes Association (ADA), San Diego demonstrated that people with type 2 diabetes achieved significantly better glycaemic control, and also achieve it earlier, when treated with the 24-hour basal insuli

  • U.S. FDA Licenses sanofi pasteur’s ADACEL™ Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis

    First and Only Booster in the U.S. for Protection against Pertussis from Adolescence through Adulthood Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has licensed ADACEL™ (Tetanus Toxoid and Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed) Vaccine for protection against tetanus, d

  • SANOFI-AVENTIS JOINS THE PARIS 2012 « CLUB DES ENTREPRISES » BACKING THE PARIS BID TO HOST THE 2012 OLYMPIC AND PARALYMPIC GAMES

    Sanofi-aventis, The world’s third largest pharmaceutical group, is joining the Paris 2012 Corporate Club in support of the Paris candidature to host the 2012 Olympic and Paralympic Games. As of today, 20 major companies of international stature - Accenture, Accor, Airbus, Air France, Bouygues, Carrefour, Crédit Agricole, EDF, France Télécom, Gaz de France, Lafarge, Lagardère, LVMH, Publicis, RA

  • ANNUAL GENERAL MEETING

    The Annual General Meeting of sanofi-aventis shareholders was held on May 31, 2005. The General Meeting approved the financial statements for the year ended December 31,2004. Also approved was the distribution of a net dividend of 1.20 euro per share, a 17.6% increase over the previous year. The dividend will be paid out on June 7, 2005. The General Meeting has reappointed PricewaterhouseCoope

  • World Heart Federation och sanofi-aventis förenar sina krafter för att förebygga uppkomsten av hjärt–kärlsjukdomar

    Paris, Frankrike & Genève, Schweiz – 23 maj 2005 - World Heart Federation och sanofi-aventis tillkännagav idag att de har ingått ett treårigt partnerskapsavtal för att med förenade krafter förbättra förebyggandet och kontrollen av hjärt–kärlsjukdomar. Tillkännagivandet gjordes vid World Heart Federations sjätte internationella kongress om förebyggande kardiologi (ICPC) i Brasilien, och bekräf

  • New study results further enhances the role of Eloxatin® in early and advanced stages of colon cancer

    Major data presented at ASCO 2005 on Eloxatin® in combination with other chemotherapeutic drugs and with new targeted agents Paris, France – May 18, 2005 - Sanofi-aventis announced today the results of key trials on the anti-cancer drug Eloxatin® (oxaliplatin for injection), presented at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. The study f

  • Taxotere® regimen demonstrates significant survival benefit in the treatment of advanced gastric cancer

    Contact : Anne Bancillon 33-6-86-31-03-89 ~ Taxotere®-Based Chemotherapy Reduces Risk of Death by 23 Percent ~ – Final results from the largest international study in the reatment of advanced stomach cancer, also known as gastric cancer, demonstrated that patients who received a Taxotere® (docetaxel) Injection Concentrate-based chemotherapy regimen (Taxotere®, cisplatin and 5-fluorouracil)

  • 2005 first-quarter net sales growth ahead of world pharmaceutical

    market growth1 at 11.9%2 on a comparable basis Strong growth in adjusted EPS3: up 27.7%2 at 1.06 euros per share Sanofi-aventis on track to meet 2005 guidance The consolidated statement of income of sanofi-aventis for the first quarter of 2005, presented in Appendix 4, shows net income of 531 million euros and is impacted by the accounting treatment of the combination with Aventis and by re

  • “1st year results of RIO-EUROPE study published in the Lancet”.

    Press release from Professor Luc Van Gaal (University Hospital Antwerp), principal investigator of the Rio-Europe trial, entitled: “1st year results of RIO-EUROPE study published in the Lancet”. Best regards, Media Relations Department 174, avenue de France - 75013 PARIS - FRANCE - Tél. : +33 1.53.77.40.00 - Fax : +33 1.53.77.41.33 - www.sanofi-aventis.com Sanofi-aventis - Siège Social :

  • Sanofi-aventis affirms its commitment to Access to Medicines in the "Southern countries", with a policy of tiered drug prices geared to populations incomes

    Contact : Dr. Robert SEBBAG +33 (0)1 53 77 47 80 +33 (0)6 08 17 21 83 EMBARGO UNTIL APRIL 15, 2005 – 1:00 p.m. (CET) In his address to the closing plenary session of BioVision – the World Life Sciences Forum - Jean-François Dehecq, Chairman and CEO of sanofi-aventis, set out the guiding principles of his Group's strategy in its Policy of Access to Medicines in the "Southern Countries".

  • FDA issues approvable letter for Ambien CR™ CIV for teh treatment of insomnia

    FDA ISSUES APPROVABLE LETTER FOR AMBIEN CR™ (ZOLPIDEM TARTRATE EXTENDED RELEASE) CIV FOR THE TREATMENT OF INSOMNIA Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for AMBIEN CR™ (zolpidem tartrate extended release) CIV. AMBIEN CR™ is the controlled-release formulation of zolpidem, the world’s

  • Sanofi pasteur awarded $97 million HHS contract to accelerate cell-culture pandemic influenza vaccine development

    Major U.S. public health initiative complements sanofi pasteur’s leadership in global pandemic preparedness Sanofi pasteur, the vaccines business of the sanofi-aventis Group, has been awarded a $97 million contract from the U.S. Health and Human Services Department (HHS) to speed the production process for new cell culture influenza vaccines in the U.S. and the design of a U.S.-based cell-cultu

Visa mer
Fyll i din epostadress för att följa Sanofi

När du väljer att skapa ett konto och följa ett nyhetsrum kommer dina personuppgifter behandlas av oss och av ägaren av nyhetsrummet för att du ska kunna motta nyheter och uppdateringar enligt dina bevakningsinställningar.

För att läsa mer om detta, var vänlig läs vår Integritetspolicy som berör vår behandling av dina personuppgifter, och Integritetspolicy för Contacts som berör behandlingen av dina personuppgifter från ägaren av nyhetsrummet du följer.

Vänligen notera att våra Användarvillkor gäller alla våra tjänster.

Du kan dra tillbaka ditt samtycke när som helst genom att avregistrera dig eller genom att ta bort ditt konto.
Kolla din inkorg

Mejl skickat till __email__. Klicka på länken i mejlet för att följa Sanofi.

Okej